EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 191 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $318,000 | -30.3% | 6,635 | -33.1% | 0.02% | -39.3% |
| Q1 2020 | $456,000 | -28.1% | 9,920 | -6.0% | 0.03% | +12.0% |
| Q4 2019 | $634,000 | +17.6% | 10,550 | +10.8% | 0.02% | +4.2% |
| Q3 2019 | $539,000 | -42.1% | 9,525 | -43.0% | 0.02% | -33.3% |
| Q2 2019 | $931,000 | -35.3% | 16,725 | -12.1% | 0.04% | +2.9% |
| Q2 2018 | $1,440,000 | +14.1% | 19,030 | -20.6% | 0.04% | +25.0% |
| Q1 2018 | $1,262,000 | -9.1% | 23,955 | -7.9% | 0.03% | 0.0% |
| Q4 2017 | $1,389,000 | -11.0% | 26,005 | -0.7% | 0.03% | -12.5% |
| Q3 2017 | $1,561,000 | – | 26,180 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |